WEBULL
WebtradeDownload

Revvity (RVTY) Launches T1D Screening Kit, Is The Upside Already Priced In?

Simply Wall St · 1d ago

Revvity’s T1D Screening Launch Puts Focus Back on the Business

Revvity (RVTY) has introduced its CE-IVDR-certified GSP T1D 3plex kit, an automated assay aimed at population-wide screening to spot children at risk of type 1 diabetes before symptoms appear.

The product runs on the group’s existing GSP instrument and uses capillary dried blood spots, which are already familiar in newborn screening workflows. That keeps the conversation on how Revvity’s installed base and diabetes-focused portfolio could matter for long-term investors, rather than on short-term trading moves.

Revvity’s launch comes as the share price has climbed 35.82% over the past 90 days and 53.96% year to date, while the 1-year total shareholder return of 79.96% and 3-year total shareholder return of 41.30% point to momentum that long-term holders will be weighing against a 5-year total shareholder return that is still down 10.61%.

Spot similar diabetes and diagnostics stories in motion by scanning our hand picked 38 healthcare AI stocks for ideas beyond Revvity.

After a move like this, some investors will feel pressure to lock in exposure to Revvity right away, while others prefer to wait for a pullback. The valuation work now shows what each camp is really choosing between.

Most Popular Narrative: 20% Overvalued

Revvity’s last close of $151.11 sits well above the most followed fair value estimate of about $126, so anyone buying today is effectively siding against that narrative and backing a richer set of expectations.

Ongoing shift in product mix toward higher-margin, software-enabled and consumables-driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.

See why 9 investors see Revvity as 20% overvalued.

Result: Fair Value of $126 (OVERVALUED)

Still, if reimbursement changes in key markets or prolonged weakness in academic and government funding squeeze diagnostics demand, Revvity’s higher multiple could quickly look more fragile.

Find out about the key risks to this Revvity narrative.

Next Steps

If this mix of optimism and concern around Revvity leaves you unsure, review the details promptly and shape your own call with 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Revvity?

Do not stop with Revvity. Put today’s research to work by lining up a few more candidates that fit the way you like to invest.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.